Literature DB >> 2028125

A qualifier Q for the survival function to describe the prevalence of a transient condition.

M S Pepe1, G Longton, M Thornquist.   

Abstract

We propose an estimator of the prevalence of a transient condition among surviving patients using right censored data. The prevalence of opportunistic infection among surviving AIDS patients and the probability of being in tumour response following cancer therapy conditional on being alive are two examples of such functions. In essence these functions describe a major aspect of the quality of life for surviving patients and may be useful when viewed in conjunction with the survival curves themselves. The method is illustrated using data from a randomized trial of bone marrow transplant patients where the prevalence of chronic graft-versus-host disease is of interest. The non-parametric estimator which we have proposed is contrasted with estimators derived from Markov and semi-Markov models.

Entities:  

Mesh:

Year:  1991        PMID: 2028125     DOI: 10.1002/sim.4780100313

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Asymptotic theory for the Cox semi-Markov illness-death model.

Authors:  Youyi Shu; John P Klein; Mei-Jie Zhang
Journal:  Lifetime Data Anal       Date:  2007-03       Impact factor: 1.588

2.  Success of allogeneic marrow transplantation for children with severe aplastic anaemia.

Authors:  Lauri M Burroughs; Ann E Woolfrey; Barry E Storer; H Joachim Deeg; Mary E D Flowers; Paul J Martin; Paul A Carpenter; Kris Doney; Frederick R Appelbaum; Jean E Sanders; Rainer Storb
Journal:  Br J Haematol       Date:  2012-04-26       Impact factor: 6.998

3.  A competing risks approach for nonparametric estimation of transition probabilities in a non-Markov illness-death model.

Authors:  Arthur Allignol; Jan Beyersmann; Thomas Gerds; Aurélien Latouche
Journal:  Lifetime Data Anal       Date:  2013-06-27       Impact factor: 1.588

4.  A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma.

Authors:  G Brandon Gunn; Eugene J Endres; Brent Parker; Maria Pia Sormani; Giuseppe Sanguineti
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

5.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Authors:  Marcello Rotta; Barry E Storer; Firoozeh Sahebi; Judith A Shizuru; Benedetto Bruno; Thoralf Lange; Edward D Agura; Peter A McSweeney; Michael A Pulsipher; Parameswaran Hari; Richard T Maziarz; Thomas R Chauncey; Frederick R Appelbaum; Mohamed L Sorror; William Bensinger; Brenda M Sandmaier; Rainer F Storb; David G Maloney
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

6.  Personalised cancer follow-up: risk stratification, needs assessment or both?

Authors:  T Filleron; F Dalenc; A Kramar
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

7.  Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?

Authors:  S Gallo; A E Woolfrey; L M Burroughs; B E Storer; M E D Flowers; P Hari; M A Pulsipher; S Heimfeld; H-P Kiem; B M Sandmaier; R Storb
Journal:  Bone Marrow Transplant       Date:  2016-08-01       Impact factor: 5.483

8.  Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.

Authors:  Silvia Johansson; Lennart Aström; Fredrik Sandin; Ulf Isacsson; Anders Montelius; Ingela Turesson
Journal:  Prostate Cancer       Date:  2012-07-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.